论文部分内容阅读
目的：观察ＣＤ４４Ｖ６在乳腺癌中表达规律及其与预后的关系。方法：应用免疫组织化学ＳＰ法，对６０例有随访结果的女性乳腺癌组织进行ＣＤ４４Ｖ６检测。结果：乳腺浸润性癌ＣＤ４４Ｖ６阳性率（８０４％）显著高于非浸润性癌（２５％），（Ｐ＜００５）；乳腺癌有淋巴结转移组ＣＤ４４Ｖ６阳性率（８９５％）显著高于无淋巴结转移组（５４５％），（Ｐ＜００１）；ＣＤ４４Ｖ６阳性组乳腺癌患者术后５年或１０年生存率（５６５％，２１７％）显著低于ＣＤ４４Ｖ６阴性组（１００％，７１％），（Ｐ＜００５）；ＣＤ４４Ｖ６表达与患者年龄、肿瘤大小及分化程度无相关性。结论：ＣＤ４４Ｖ６表达状况，可作为临床判断乳腺癌转移潜能及患者预后的一项重要指标。
Objective: To observe the expression of CD44V6 in breast cancer and its relationship with prognosis. METHODS: Immunohistochemical SP method was used to detect CD44V6 in 60 breast cancer patients with follow-up results. Results: The positive rate of CD44V6 in breast invasive carcinoma (80.4%) was significantly higher than that in non-invasive carcinoma (25%) (P<0. 05). The positive rate of CD44V6 in breast cancer with lymph node metastasis (89.5%). Significantly higher than those without lymph node metastasis (54.5%), (P<0. 01); Postoperative 5-year or 10-year survival rates (56.5%, 21.7%) were significantly lower in patients with CD44V6-positive breast cancer. In the CD44V6-negative group (100%, 71%), (P <0. 05); CD44V6 expression and patient age, tumor size and differentiation did not correlate. Conclusion: The expression of CD44V6 can be used as an important index for judging the metastatic potential and prognosis of breast cancer.